Reata Pharmaceuticals holds a
performance score of 8 on a scale of zero to a hundred. The company holds a Beta of 1.003, which implies a somewhat significant risk relative to the market. Let's try to break down what Reata's beta means in this case. Reata Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Reata Pharmaceuticals is expected to follow. Although it is essential to pay attention to
Reata Pharmaceuticals current trending patterns, it is also good to be reasonable about what you can do with equity existing
price patterns. Our philosophy towards forecasting future potential of any stock is to look not only at its past charts but also at the business as a whole, including all
available fundamental and
technical indicators. To evaluate if Reata Pharmaceuticals expected return of 3.05 will be sustainable into the future, we have found twenty-eight different
technical indicators, which can help you to check if the expected returns are sustainable. Use Reata Pharmaceuticals
information ratio,
downside variance,
day median price, as well as the
relationship between the
treynor ratio and
kurtosis to analyze future returns on Reata Pharmaceuticals.
What is the right price you would pay to acquire a share of Reata Pharmaceuticals? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with Reata Pharmaceuticals this year
Annual and quarterly reports issued by Reata Pharmaceuticals are formal
financial statements that are published yearly and quarterly and sent to Reata stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Reata Pharmaceuticals often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Is Reata a risky opportunity?
Let's check the volatility. Reata is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Reata (USA Stocks:RETA) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. taking in a share of a Reata Pharmaceuticals stock makes you a part-owner of that company.
Reata Pharmaceuticals Current Consensus
Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Reata Pharmaceuticals. The Reata consensus assessment is calculated by taking the average estimates from all of the analysts covering Reata Pharmaceuticals
| Strong Buy | 8 | 80.0 |
| Buy | 0 | 0.0 |
| Hold | 2 | 20.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Another 3 percent rise for Reata Pharmaceuticals
Current risk adjusted performance is at 0.11.
As of the 3rd of March, Reata Pharmaceuticals holds the Semi Deviation of 5.45,
risk adjusted performance of 0.1149, and Coefficient Of Variation of 872.83. Compared to
fundamental indicators, the
technical analysis model allows you to check existing technical drivers of Reata Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen
technical drivers for Reata Pharmaceuticals, which can be compared to its competitors. Please check
Reata Pharmaceuticals treynor ratio, and the
relationship between the
standard deviation and
downside variance to decide if Reata Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 90.87 per share. Given that Reata Pharmaceuticals has
jensen alpha of 2.95, we recommend you to check out Reata Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.
Our Final Take On Reata Pharmaceuticals
Whereas few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Reata Pharmaceuticals may offer a potential longer-term growth to investors. To sum up, as of the 3rd of March 2023, our latest 90 days recommendation on the company is
Strong Hold. We believe Reata Pharmaceuticals is
overvalued with
very small probability of distress for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Reata Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com